EGFR and breast cancer: Since ErbB2 breast cancer is driven by homodimerization and/or heterodimerization of the amplified ErbB2 with other ErbB receptors, the loss of ErbB family receptors may further promote MEDICA efficacy in suppressing ErbB2 breast cancer.